PanGIA’s scalable technology demonstrates ability to detect disease-specific molecular patterns across multiple clinical biofluids

PanGIA Biotech announced today four of its abstracts were accepted for presentation at the 7th Annual Congress of Liquid Biopsy (ISLB 2025)¹, November 1–3 in Orlando, Florida. This recognition reflects PanGIA Biotech’s broad capabilities and active participation within the liquid-biopsy community.

The presentations describe how PanGIA Analysis System (PAS) detects biomolecular patterns associated with multiple diseases beyond oncology. This evolution from single-disease testing toward a unified analysis system supports PanGIA’s pipeline of diagnostic research across therapeutic areas.

Collectively, the abstracts explore applications in oncology, neurology, trauma, and rare disease—highlighting PAS’ versatility in multi-cancer early detection (MCED) and multi-disease early detection (MDED) research. Unlike blood-based approaches relying on DNA or RNA, the system analyzes colorimetric biomolecular signatures from multiple biofluids, enabling detection of disease-associated molecular patterns without sequencing. By using both urine and cerebrospinal fluid (CSF), the technology shows applicability to non-blood biofluids.

“Presenting multiple abstracts at ISLB shows the breadth of our technology and how it can generate molecular insights from easily collected biofluids,” said Obdulio Piloto, PhD, Chief Scientific Officer. “These findings contribute to the growing body of evidence supporting non-invasive approaches for earlier disease detection and monitoring.”

Posters will display in the ISLB Exhibit Hall throughout the congress; presenting authors available during morning viewing sessions: Saturday, Nov. 1 (10:30–11:30 a.m.; team available 11:30 a.m.–12:30 p.m.), Sunday, Nov. 2 (10:30–11:30 a.m.), and Monday, Nov. 3 (9:00–10:00 a.m.).

See PanGIA at ISLB to learn more about its multi-disease detection capabilities.

The research presented at ISLB 2025 is for scientific discussion only and does not represent products cleared for diagnostic use.

About PanGIA Biotech

PanGIA Biotech develops AI-integrated, urine- and CSF-based liquid biopsy solutions designed for global scalability. The PanGIA® Analysis System combines non-invasive sample collection, biomolecular-signature profiling, and machine-learning-driven pattern recognition that supports early detection, monitoring, and disease management—including cancer as early as Stage 1. Backed by patents and peer-reviewed research, PanGIA is committed to advancing innovation that supports earlier detection and better health outcomes.

¹ Source: ISLB 2025 Abstract Acceptance Notification (Abstracts 77–80), 7th Annual Congress of Liquid Biopsy, Orlando, Nov. 1–3 2025.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251030211292/en/

“These findings contribute to the growing body of evidence supporting non-invasive approaches for earlier disease detection and monitoring.”